课题基金 / 基金详情

Adenosine receptor-mediated effects of Clostridium difficile toxins in humans

Adenosine receptor-mediated effects of Clostridium difficile toxins in humans
腺苷受体介导的艰难梭菌毒素对人体的影响
批准号:
9177910
负责人:
Cirle Alcantara Warren
金额:
$23.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-21 至 2018-05-31

项目摘要

项目成果

Cirle Alcantara Warren的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Clostridium difficile infection (CDI) is the single most common cause of infectious antibiotic-induced diarrhea. The primary virulence factors that are known to cause CDI are the two toxins: TcdA and TcdB. These toxins incite intense inflammation of the intestinal tissue and in severe cases, of the systemic circulation. Adenosine is released in increased amounts during tissue injury and its action is mediated by four receptors—A1, A2A, A2B and A3 adenosine receptors (AR). We have shown that TcdA and TcdB upregulate A2BAR and to lesser extent, A2AAR, transcript expression in a human intestinal cell line. Inhibition or deletion of A2BARs decreases TcdA-induced secretion and mucosal injury in ileal loops and in infected mice. While both A2AARs and A2BARs are known to be present in immune cells, gut epithelial cells express higher levels of A2BAR transcript than other cell types. We hypothesize that adenosine, through its interactions with A2BAR and A2AAR, modulates host responses to C. difficile toxins. Pharmacologic manipulation of these adenosine receptors will ameliorate toxin-induced epithelial injury and improve outcomes during infection. In this proposal, we shall determine how A2BAR inhibition regulates the local inflammatory responses to C. difficile toxins in primary human intestinal tissue (Aim 1). We shall also determine how A2AAR activation modulates systemic inflammatory responses to C. difficile toxins in human neutrophils (Aim 2). This research plan will provide insight into how A2AAR and A2BAR signaling mediate host immune responses to C. difficile toxins and how manipulation of these receptors may provide novel, non-antimicrobial, host-directed approaches to treating CDI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Disulfiram for Entameoba histolytica Enteric Diarrhea [DEED] Trial
  • 批准号:
    10328369
  • 项目类别:
  • 资助金额:
    $24.39万
  • 财政年份:
    2022
  • 负责人:
    Cirle Alcantara Warren
  • 依托单位:
Alanyl-glutamine supplementation of standard treatment for C. difficile infection
  • 批准号:
    10214449
  • 项目类别:
  • 资助金额:
    $80.32万
  • 财政年份:
    2020
  • 负责人:
    Cirle Alcantara Warren
  • 依托单位:
Alanyl-glutamine supplementation of standard treatment for C. difficile infection
  • 批准号:
    10443734
  • 项目类别:
  • 资助金额:
    $80.54万
  • 财政年份:
    2020
  • 负责人:
    Cirle Alcantara Warren
  • 依托单位:
Alanyl-glutamine supplementation of standard treatment for C. difficile infection
  • 批准号:
    10670117
  • 项目类别:
  • 资助金额:
    $79.58万
  • 财政年份:
    2020
  • 负责人:
    Cirle Alcantara Warren
  • 依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
  • 批准号:
    82074359
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    安晓飞
  • 依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制